Skip to main content

Table 7 Reimbursement rate changes from the pre- to the post-action period

From: The influences of Taiwan's generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-used classes of cardiovascular drugs

Beta blocking agents  
Number of all kinds covered by the NHI in the pre- or the post-action period 170
Number of kinds with price reduction after the action 65
% of kinds with price reduction after the action 38.24%
The average level of price reduction (%) of those with reduced prices 16.67%
Calcium channel blockers, vascular effects  
Number of all kinds covered by the NHI in the pre- or the post-action period 74
Number of kinds with price reduction after the action 48
% of kinds with price reduction after the action 64.86%
The average level of price reduction (%) of those with reduced prices 12.87%
ACE inhibitors, plain  
Number of all kinds covered by the NHI in the pre- or the post-action period 95
Number of kinds with price reduction after the action 50
% of kinds with price reduction after the action 52.63%
The average level of price reduction (%) of those with reduced prices 11.36%